These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 28135237)

  • 1. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.
    He Y; Selvaraju S; Curtin ML; Jakob CG; Zhu H; Comess KM; Shaw B; The J; Lima-Fernandes E; Szewczyk MM; Cheng D; Klinge KL; Li HQ; Pliushchev M; Algire MA; Maag D; Guo J; Dietrich J; Panchal SC; Petros AM; Sweis RF; Torrent M; Bigelow LJ; Senisterra G; Li F; Kennedy S; Wu Q; Osterling DJ; Lindley DJ; Gao W; Galasinski S; Barsyte-Lovejoy D; Vedadi M; Buchanan FG; Arrowsmith CH; Chiang GG; Sun C; Pappano WN
    Nat Chem Biol; 2017 Apr; 13(4):389-395. PubMed ID: 28135237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
    Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
    Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding Modes of Small-Molecule Inhibitors to the EED Pocket of PRC2.
    Huang D; Tian S; Qi Y; Zhang JZH
    Chemphyschem; 2020 Feb; 21(3):263-271. PubMed ID: 31816138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.
    Curtin ML; Pliushchev MA; Li HQ; Torrent M; Dietrich JD; Jakob CG; Zhu H; Zhao H; Wang Y; Ji Z; Clark RF; Sarris KA; Selvaraju S; Shaw B; Algire MA; He Y; Richardson PL; Sweis RF; Sun C; Chiang GG; Michaelides MR
    Bioorg Med Chem Lett; 2017 Apr; 27(7):1576-1583. PubMed ID: 28254486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment.
    Cook N; Chen J; Zhou J; Wu D
    Curr Top Med Chem; 2021; 21(31):2771-2777. PubMed ID: 34544341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2.
    Barnash KD; The J; Norris-Drouin JL; Cholensky SH; Worley BM; Li F; Stuckey JI; Brown PJ; Vedadi M; Arrowsmith CH; Frye SV; James LI
    ACS Comb Sci; 2017 Mar; 19(3):161-172. PubMed ID: 28165227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction.
    Du D; Xu D; Zhu L; Stazi G; Zwergel C; Liu Y; Luo Z; Li Y; Zhang Y; Zhu K; Ding Y; Liu J; Fan S; Zhao K; Zhang N; Kong X; Jiang H; Chen K; Zhao K; Valente S; Min J; Duan W; Luo C
    J Med Chem; 2021 Jun; 64(12):8194-8207. PubMed ID: 34077206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED.
    Li L; Zhang H; Zhang M; Zhao M; Feng L; Luo X; Gao Z; Huang Y; Ardayfio O; Zhang JH; Lin Y; Fan H; Mi Y; Li G; Liu L; Feng L; Luo F; Teng L; Qi W; Ottl J; Lingel A; Bussiere DE; Yu Z; Atadja P; Lu C; Li E; Gu J; Zhao K
    PLoS One; 2017; 12(1):e0169855. PubMed ID: 28072869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).
    Yang CY; Wang S
    J Med Chem; 2017 Mar; 60(6):2212-2214. PubMed ID: 28256832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.
    Huang Y; Zhang J; Yu Z; Zhang H; Wang Y; Lingel A; Qi W; Gu J; Zhao K; Shultz MD; Wang L; Fu X; Sun Y; Zhang Q; Jiang X; Zhang J; Zhang C; Li L; Zeng J; Feng L; Zhang C; Liu Y; Zhang M; Zhang L; Zhao M; Gao Z; Liu X; Fang D; Guo H; Mi Y; Gabriel T; Dillon MP; Atadja P; Oyang C
    J Med Chem; 2017 Mar; 60(6):2215-2226. PubMed ID: 28092155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.
    Catalano R; Rocca R; Juli G; Costa G; Maruca A; Artese A; Caracciolo D; Tagliaferri P; Alcaro S; Tassone P; Amodio N
    Eur J Med Chem; 2019 Dec; 183():111715. PubMed ID: 31550663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.
    Zhu K; Du D; Yang R; Tao H; Zhang H
    Chem Pharm Bull (Tokyo); 2020 Jan; 68(1):58-63. PubMed ID: 31685780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.
    Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH
    Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Allosteric PRC2 Inhibitor Targeting EED Suppresses Tumor Progression by Modulating the Immune Response.
    Dong H; Liu S; Zhang X; Chen S; Kang L; Chen Y; Ma S; Fu X; Liu Y; Zhang H; Zou B
    Cancer Res; 2019 Nov; 79(21):5587-5596. PubMed ID: 31395608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-323-3p regulates the activity of polycomb repressive complex 2 (PRC2) via targeting the mRNA of embryonic ectoderm development (Eed) gene in mouse embryonic stem cells.
    Zhang Y; Teng F; Luo GZ; Wang M; Tong M; Zhao X; Wang L; Wang XJ; Zhou Q
    J Biol Chem; 2013 Aug; 288(33):23659-65. PubMed ID: 23821546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
    Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
    Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
    Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
    Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
    Bagal SK; Gregson C; O' Donovan DH; Pike KG; Bloecher A; Barton P; Borodovsky A; Code E; Fillery SM; Hsu JH; Kawatkar SP; Li C; Longmire D; Nai Y; Nash SC; Pike A; Robinson J; Read JA; Rawlins PB; Shen M; Tang J; Wang P; Woods H; Williamson B
    J Med Chem; 2021 Dec; 64(23):17146-17183. PubMed ID: 34807608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.
    Zhang KL; Shen QQ; Fang YF; Sun YM; Ding J; Chen Y
    Acta Pharmacol Sin; 2019 Dec; 40(12):1587-1595. PubMed ID: 31171828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.